The long-awaited “Sunshine Act” regulations are the latest in the federal government’s increasing list of regulatory requirements imposed on pharmaceutical manufacturers over the last 20-plus years.  Many questions remain about the scope of the proposed regulations requiring reporting and disclosure of manufacturer payments to physicians and teaching hospitals, as well their practical application.  Nevertheless, manufacturers must take steps now to prepare for their eventuality, including beefing up compliance departments that some in management probably view as already glutted.
[Read more...]